Primex Pharmaceuticals AG, a Switzerland-based pharmaceutical company, has named Dan Spacie as its new global commercial head, it was reported yesterday.
Dan Spacie joined Primex Pharmaceuticals from Syneos Health, where he was president, Commercial, Europe. Prior to Syneos, he held several leadership roles including managing director at STADA UK affiliates for five years. He has extensive international leadership experience in growing sales and enhancing profitability of generics, branded pharmaceuticals and launching biopharmaceuticals.
In the new role, Spacie is responsible for global Commercialisation, working with both the company's partners and direct field forces across the portfolio and with the launch of OZALIN in the European Union. He will be part of the executive team headed by CEO Alan Knox and is based in Zug, Switzerland.
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval
Newbury Pharmaceuticals gains Finnish approval for generic melatonin
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)